"Administration, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The giving of drugs, chemicals, or other substances by mouth.
| Descriptor ID |
D000284
|
| MeSH Number(s) |
E02.319.267.100
|
| Concept/Terms |
Administration, Oral- Administration, Oral
- Drug Administration, Oral
- Oral Drug Administration
- Oral Administration
- Administrations, Oral
- Oral Administrations
- Administration, Oral Drug
- Administrations, Oral Drug
- Drug Administrations, Oral
- Oral Drug Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Oral".
Below are MeSH descriptors whose meaning is more specific than "Administration, Oral".
This graph shows the total number of publications written about "Administration, Oral" by people in this website by year, and whether "Administration, Oral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 16 | 16 |
| 1998 | 0 | 14 | 14 |
| 1999 | 0 | 15 | 15 |
| 2000 | 0 | 7 | 7 |
| 2001 | 0 | 18 | 18 |
| 2002 | 0 | 22 | 22 |
| 2003 | 0 | 19 | 19 |
| 2004 | 0 | 15 | 15 |
| 2005 | 0 | 16 | 16 |
| 2006 | 0 | 10 | 10 |
| 2007 | 0 | 19 | 19 |
| 2008 | 0 | 13 | 13 |
| 2009 | 0 | 17 | 17 |
| 2010 | 0 | 14 | 14 |
| 2011 | 0 | 17 | 17 |
| 2012 | 0 | 11 | 11 |
| 2013 | 0 | 17 | 17 |
| 2014 | 0 | 15 | 15 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 21 | 21 |
| 2017 | 0 | 18 | 18 |
| 2018 | 0 | 26 | 26 |
| 2019 | 0 | 19 | 19 |
| 2020 | 0 | 19 | 19 |
| 2021 | 0 | 15 | 15 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 8 | 8 |
| 2025 | 0 | 10 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Oral" by people in Profiles.
-
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 Jan; 40(1):99-109.
-
Connectome-based encoding of subjective drug responses to acute oral methamphetamine. Neuropsychopharmacology. 2025 Nov; 50(12):1787-1794.
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 Aug 19; 68(1):e116.
-
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial. CNS Drugs. 2025 Sep; 39(9):865-877.
-
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. N Engl J Med. 2025 Jun 19; 392(23):2346-2356.
-
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. Br J Haematol. 2025 Aug; 207(2):432-444.
-
The safety and efficacy of a single dose of oral azithromycin given in labour to prevent skin and soft tissue infections in young infants in Fiji: a randomised controlled trial. BMC Med. 2025 Apr 28; 23(1):246.
-
Valacyclovir Pharmacokinetics in Infants With Neonatal Herpes Simplex Virus Disease. Pediatr Infect Dis J. 2025 Apr 10; 44(9):860-865.
-
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J. 2025 Mar 31; 15(1):50.
-
Effect of postpartum oral furosemide use on postpartum readmissions and blood pressure trends. Pregnancy Hypertens. 2025 Mar; 39:101199.